Trial Profile
Pharmacoscintigraphic Investigation NN9924 in Healthy Male Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 18 May 2021
Price :
$35
*
At a glance
- Drugs Semaglutide (Primary)
- Indications Alzheimer's disease; Obesity; Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Novo Nordisk
- 10 May 2021 Results of pooled analysis assessing clinical pharmacokinetics of oral Semaglutide published in the Clinical Pharmacokinetics
- 15 Sep 2017 Results of this and other study assessing absorption of semaglutide, presented at the 53rd Annual Meeting of the European Association for the Study of Diabetes.
- 15 Sep 2017 Results presented at the 53rd Annual Meeting of the European Association for the Study of Diabetes